— Avid Bioservices (NASDAQ: CDMO) reported a loss of $0.## per share for its third quarter of 2020 vs. expected loss of $0.04 per share.
— Revenue was $13.6 million vs. $15.42 million expected.
— As of January 31, 2020, revenue backlog was approximately $58 million.
— For fiscal 2020, the company reduced its revenue outlook to a range of $55 million to $59 million from the previously issued guidance of $64 million to $67 million.
— Avid Bioservices stated that the temporary production interruption resulted in lower revenue and profits for the third quarter. This interruption is also expected to impact revenues and profits for the fourth quarter of fiscal 2020.
— CDMO shares plummeted more than 15% during the after-hours.
Most Popular
Docusign (DOCU) Earnings: 3Q26 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported its earnings results for the third quarter of 2026. Revenue increased 8% year-over-year to $818.4 million. GAAP net income was $83.7 million, or $0.40
Infographic: How Ulta Beauty (ULTA) performed in Q3 2025
Ulta Beauty, Inc. (NASDAQ: ULTA) reported its earnings results for the third quarter of 2025. Net sales increased 12.9% year-over-year to $2.9 billion, driven by comparable sales growth, the Space
Hewlett Packard Enterprise (HPE) Earnings: 4Q25 Key Numbers
Hewlett Packard Enterprise (NYSE: HPE) reported revenue of $9.7 billion for the fourth quarter of 2025, up 14% from the prior-year period in actual dollars and in constant currency. Net
Comments
Comments are closed.